Allergy Therapeutics has announced that all foreign direct investment (FDI) clearance conditions have been satisfied in relation to its equity financing. The financing, which will raise gross proceeds of £40.75 million, consists of a subscription and an open offer. The proceeds will be used to repay outstanding debt. A shareholder circular outlining the terms and conditions of the open offer will be published in the next five business days. The financing is conditional on the admission of the subscription shares and the open offer shares to trading on AIM. The company also provided an update on its funding, stating that additional funding may be required in November and possibly into early 2024. Discussions with significant shareholders for additional funding are ongoing.